HOME >> BIOLOGY >> NEWS
Scientists discover that metastases share a similar genetic profile to their primary tumour

Hamburg, Germany: Work by scientists in The Netherlands has contradicted the notion that breast cancer metastases behave differently to their primary tumours.

PhD student, Britta Weigelt told the meeting of the 4th European Breast Cancer Conference today (Thursday 18 March) that, contrary to what had been thought previously, any primary breast cancer cell was capable of producing secondary cancer cells, which then spread to other parts of the body. These secondary cancer cells had a strikingly similar genetic make-up to their parent cells and behaved in a similar way. Therefore, metastases were likely to have the same response to a particular treatment as their primary tumour.

The discovery has implications for the treatment of breast cancer once researchers have identified the ways that genetically different tumours respond to a variety of therapies. Based on the genetic profile of a patient's tumour, doctors could choose the best treatment for that particular type of tumour (from specific types of chemo-, radio- or hormonal therapies) and treat the patient with it from the time of diagnosis. Such early (neo-adjuvant) treatment could not only shrink the primary tumour but might also prevent the outgrowth of micrometastases, thereby saving lives, as metastases that occur in other parts of the body are notoriously difficult to treat successfully and are the main cause of death in breast cancer.

Mrs Weigelt said: "Until now it was largely unknown whether the characteristics of breast cancer that define the growth rate and therapy response of the primary tumour were alike in the metastases. Furthermore, it was unclear whether all primary breast cancer cells were capable of metastasising, or only some of them."

In the first study to do this, Mrs Weigelt and her colleagues at the Netherlands Cancer Institute in Amsterdam compared the activities of genes in samples of primary breast tumours from 15 patients and in their matching lymph
'"/>

Contact: Emma Mason
wordmason@aol.com
49-403-569-3625
Federation of European Cancer Societies
18-Mar-2004


Page: 1 2

Related biology news :

1. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
2. Scientists sequence genome of kind of organism central to biospheres carbon cycle
3. Scientists find nanowires capable of detecting individual viruses
4. Scientists discover potential new way to control drug-resistant bacteria
5. Scientists explore genome of methane-breathing microbe
6. Scientists decipher genetic code of biothreat pathogen
7. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins
8. Scientists discover proteins involved in spread of HIV-1 infection
9. Scientists fear new Ebola outbreak may explain sudden gorilla disappearance
10. Scientists reinvent DNA as template to produce organic molecules
11. Scientists visualise cellular handmaiden that restores shape to proteins

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016 /PRNewswire/ ... Partner, launched this week highlighting advancements in flexible, ... – a record setting attendance - have gathered ... in this fast-growing field of electronics. The Flex ... a focal point for companies, R&D organizations, and ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... N.J. , May 4, 2016  Bayer ... its oncology compound Stivarga ® (regorafenib) tablets ... carcinoma (HCC) has met its primary endpoint of ... study, called RESORCE, evaluated the efficacy and safety ... has progressed after treatment with sorafenib. The safety ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... growth, has leveraged recent innovations in biotechnology to help treat hormonal and stress ... hair loss, Nutrafol® has captured the hearts of key opinion leaders in the ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/3/2016)... -- - And Other Rising Companies - ... Competitor Biologics  - Biosimilar Drug Producers - ... Who are the most important and promising ... sales potentials? Discover, in our updated survey, organisations, outlooks ... revenue forecasting. Visiongain,s new study ...
Breaking Biology Technology:
Cached News: